At ESC HF 2024 in Lisbon, during an oral presentation, new data data of our CRF2 peptide agonist COR-1167 were released. On top of furosemide, COR-1167 reduced elevated cardiac filling and venous pressures, increased diuresis, decreased body weight and improved renal function in a worsening heart failure sheep model, even under conditions of fluid overload. COR-1167 represents a promising new treatment for WHF.